| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2007 | CA2646236A1 Novel formulations |
| 09/27/2007 | CA2646229A1 Deuterated hepatitis c protease inhibitors |
| 09/27/2007 | CA2646227A1 Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them |
| 09/27/2007 | CA2646222A1 Nitrofuran compounds for the treatment of cancer and angiogenesis |
| 09/27/2007 | CA2646207A1 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
| 09/27/2007 | CA2646204A1 Substituted 2-amino-4-phenyl-dihydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them |
| 09/27/2007 | CA2646170A1 Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |
| 09/27/2007 | CA2646156A1 Treatment of triple receptor negative breast cancer |
| 09/27/2007 | CA2646149A1 Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
| 09/27/2007 | CA2646124A1 Pharmaceutically acceptable salts and polymorphic forms |
| 09/27/2007 | CA2646067A1 Stabilized, sterilized collagen scaffolds with active adjuncts attached |
| 09/27/2007 | CA2646065A1 Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| 09/27/2007 | CA2646007A1 Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use |
| 09/27/2007 | CA2646002A1 Salts with crth2 antagonist activity |
| 09/27/2007 | CA2645940A1 Controlled release formulation of tolterodine |
| 09/27/2007 | CA2645892A1 Substituted indazole derivatives, their manufacture and use as pharmaceutical agents |
| 09/27/2007 | CA2645867A1 Substituted gamma lactams as prostaglandin ep2 agonists |
| 09/27/2007 | CA2645731A1 N-substituted-azacyclylamines as histamine-3 antagonists |
| 09/27/2007 | CA2645728A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 09/27/2007 | CA2645652A1 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | CA2645583A1 Methods of inhibiting btk and syk protein kinases |
| 09/27/2007 | CA2645556A1 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | CA2645551A1 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 09/27/2007 | CA2645546A1 Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases |
| 09/27/2007 | CA2645434A1 Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| 09/27/2007 | CA2645422A1 Methods of treating cancer using hypofractionated radiation and texaphyrins |
| 09/27/2007 | CA2645329A1 Use of e-3-[3-[n-(4-methoxybenzenesulfonyl)-n-isopropylamino]phenyl]-3-(3-pyridyl)propenohydroxamic acid for preparing a medicament for preventing and/or treating inflammatory skin pathologies |
| 09/27/2007 | CA2645327A1 Use of (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide for treating inflammatory skin pathologies |
| 09/27/2007 | CA2644716A1 Ophthalmic compositions for treating ocular hypertension |
| 09/27/2007 | CA2644649A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
| 09/27/2007 | CA2644643A1 Inhibitors of the interaction between mdm2 and p53 |
| 09/27/2007 | CA2644356A1 Heterocyclic organic compounds for the treatment of in particular melanoma |
| 09/27/2007 | CA2644347A1 Small internally segmented interfering rna |
| 09/27/2007 | CA2644303A1 Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones |
| 09/27/2007 | CA2644207A1 Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders |
| 09/27/2007 | CA2644181A1 Prophylactic or therapeutic agent for irritable bowel syndrome |
| 09/27/2007 | CA2644132A1 Flavivirus inhibition by sultams and related compounds |
| 09/27/2007 | CA2643968A1 Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof |
| 09/27/2007 | CA2643944A1 Solid dosage form containing a taste masked active agent |
| 09/27/2007 | CA2643937A1 Salt of aliskiren with sulfuric acid |
| 09/27/2007 | CA2643785A1 Extracts and methods comprising ganoderma species |
| 09/27/2007 | CA2640978A1 Contraceptive composition |
| 09/27/2007 | CA2637137A1 A novel method of protecting islet cells from apoptosis during the donor harvesting process |
| 09/26/2007 | EP1837399A1 Anticancer agent |
| 09/26/2007 | EP1837398A1 Drugs for diseases accompanying changes in total bile acid pool or lipid metabolism disorders and method of screening these drugs |
| 09/26/2007 | EP1837342A2 Sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 09/26/2007 | EP1837337A1 Novel crystalline polymorphs of clopidogrel |
| 09/26/2007 | EP1837332A1 Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| 09/26/2007 | EP1837330A1 Benzamide inhibitors of the P2X7 receptor |
| 09/26/2007 | EP1837329A1 Novel heteroaryl derivative |
| 09/26/2007 | EP1837035A1 Therapeutic agent for chronic obstructive pulmonary disease (copd), cystic fibrosis or pulmonary hypertension |
| 09/26/2007 | EP1837034A1 Remedy for alzheimer´s disease |
| 09/26/2007 | EP1837033A1 REMEDY FOR DIABETES CONTAINING Cdk5 INHIBITOR |
| 09/26/2007 | EP1837031A1 Compositions and methods for treating diabetes |
| 09/26/2007 | EP1837030A1 Phospholipid complexes of curcumin having improved bioavailability |
| 09/26/2007 | EP1837027A1 Iridoid glycoside composition |
| 09/26/2007 | EP1837026A1 Hepatic function remedial agent |
| 09/26/2007 | EP1837025A2 Method of treating cancer using kinase inhibitors |
| 09/26/2007 | EP1837024A2 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
| 09/26/2007 | EP1837023A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 09/26/2007 | EP1837022A1 Indolomorphinan derivative having carboxy in 6'-position |
| 09/26/2007 | EP1837021A2 Inhalative solution formulation containing a tiotropium salt |
| 09/26/2007 | EP1837020A1 Mucosal bioadhesive slow release carrier for delivering active principles |
| 09/26/2007 | EP1837019A1 Orally-dispersible pharmaceutical compositions |
| 09/26/2007 | EP1837017A2 Microparticles for delivery of nucleic acid |
| 09/26/2007 | EP1837016A2 Pharmaceutical multiple-unit composition |
| 09/26/2007 | EP1836807A2 Inhibitors of checkpoint kinases |
| 09/26/2007 | EP1836310A2 Method for producing probiotically derived compounds |
| 09/26/2007 | EP1836305A1 Expression vectors for treating bacterial infections |
| 09/26/2007 | EP1836304A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and uses thereof |
| 09/26/2007 | EP1836215A1 Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions |
| 09/26/2007 | EP1836211A1 Macrolides |
| 09/26/2007 | EP1836208A2 AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
| 09/26/2007 | EP1836207A2 Triazolophthalazines as pde2-inhibitors |
| 09/26/2007 | EP1836206A1 Azolopyrimidine-based inhibitors of dipeptidyl peptidase iv and methods |
| 09/26/2007 | EP1836203A2 Heteroaryl substituted quinolin-4-ylamine analogues |
| 09/26/2007 | EP1836202A2 Aminophenyl derivatives as selective androgen receptor modulators |
| 09/26/2007 | EP1836201A1 Pyrrolidine inhibitors of iap |
| 09/26/2007 | EP1836200A1 Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof |
| 09/26/2007 | EP1836199A1 Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases |
| 09/26/2007 | EP1836198A1 Substituted pyrrolidinones having an antithrombotic effect, the production thereof and their use as medicaments |
| 09/26/2007 | EP1836197A1 Selective muscle relaxant and pharmaceutical compositions |
| 09/26/2007 | EP1836196A1 Tricyclic delta-opioid modulators |
| 09/26/2007 | EP1836194A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy |
| 09/26/2007 | EP1836191A1 Pyrazolylamino substituted quinazoles for the treatment of cancer |
| 09/26/2007 | EP1836189A1 Novel pyridine compounds |
| 09/26/2007 | EP1836188A1 Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| 09/26/2007 | EP1836187A1 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists |
| 09/26/2007 | EP1836183A2 Spiro derivatives as lipoxygenase inhibitors |
| 09/26/2007 | EP1836182A2 Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| 09/26/2007 | EP1836180A2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs |
| 09/26/2007 | EP1836178A1 Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 09/26/2007 | EP1836177A2 Vitamin d receptor modulators |
| 09/26/2007 | EP1836176A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEROF |
| 09/26/2007 | EP1836175A2 Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| 09/26/2007 | EP1836173A2 Anti-inflammatory medicaments |
| 09/26/2007 | EP1836172A1 5-ht7 receptor antagonists |
| 09/26/2007 | EP1836170A1 N-((2z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2 |
| 09/26/2007 | EP1836168A1 Benzoyl-tetrahydropyridine as glyt-1 inhibitors |
| 09/26/2007 | EP1836166A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |